{"id":"amg-714","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL2109249","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"AMG 714 binds to and inhibits the IL-6 receptor, preventing IL-6-mediated inflammatory signaling. This mechanism is intended to reduce systemic inflammation in autoimmune and inflammatory conditions. By blocking IL-6, the drug aims to suppress the inflammatory cascade that drives disease pathology in conditions like rheumatoid arthritis and other IL-6-driven inflammatory disorders.","oneSentence":"AMG 714 is an interleukin-6 (IL-6) receptor antagonist that blocks IL-6 signaling to reduce inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:08:40.449Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Systemic lupus erythematosus"}]},"trialDetails":[{"nctId":"NCT04338581","phase":"PHASE2","title":"Evaluation of AMG 714 for Vitiligo","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-11","conditions":"Vitiligo","enrollment":60},{"nctId":"NCT03439475","phase":"","title":"AMG 714 Expanded Access Program","status":"NO_LONGER_AVAILABLE","sponsor":"Amgen","startDate":"","conditions":"Celiac Disease","enrollment":""},{"nctId":"NCT02633020","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-04-13","conditions":"Type II Refractory Celiac Disease (RCD-II), In-situ Small Bowel T-cell Lymphoma","enrollment":28},{"nctId":"NCT02637141","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-04-13","conditions":"Celiac Disease","enrollment":64},{"nctId":"NCT00443326","phase":"PHASE2","title":"AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-03","conditions":"Psoriasis","enrollment":22},{"nctId":"NCT00433875","phase":"PHASE2","title":"Phase 2 AMG 714 in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PRV-015"],"phase":"phase_2","status":"active","brandName":"AMG 714","genericName":"AMG 714","companyName":"Amgen","companyId":"amgen","modality":"Biologic","firstApprovalDate":"","aiSummary":"AMG 714 is an interleukin-6 (IL-6) receptor antagonist that blocks IL-6 signaling to reduce inflammation. Used for Rheumatoid arthritis, Systemic lupus erythematosus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}